Solution
G-Plume provides strategic advisory support for rare disease programs, focusing on development pathway design, regulatory alignment, and risk structuring. Advisory engagements are designed to complement the platform by guiding early decision-making and long-term portfolio strategy.
Patient Registry Platform
G-Plume’s Patient Registry Platform enables systematic patient identification and longitudinal data collection for rare and ultra-rare diseases. By integrating clinical, genomic, and real-world data sources, the platform transforms fragmented information into standardized, research-ready assets. This foundation supports precision patient matching, multi-channel recruitment, and faster study start-up across global development programs.
Natural History & Real‑World Evidence
G-Plume designs and executes regulatory-grade natural history and real-world evidence programs to address critical data gaps in rare disease development. These programs support endpoint validation, trial design optimization, and regulatory engagement. Where applicable, real-world evidence pathways—such as Hainan Lecheng—are leveraged to accelerate registration timelines and reduce late-stage uncertainty.
Hybrid Clinical Execution
Our hybrid clinical execution model integrates global patient access with region-specific operational excellence. By coordinating clinical sites across the United States, China, and other regions, G-Plume optimizes enrollment speed, data diversity, and cost efficiency. This approach enables earlier First-in-Human studies while maintaining regulatory-aligned quality standards.
Genomic
G-Plume integrates genomic profiling with real-world clinical data to accelerate rare disease identification and precision development planning. Our platform enables early biomarker discovery, patient stratification, and evidence generation, supporting regulatory readiness and global access strategies from the earliest stages of development.
Regulatory
Regulatory strategy is embedded early within the platform to ensure alignment across data generation, clinical execution, and evidence requirements. G-Plume supports regulatory interactions, pathway planning, and submission-ready data structures throughout development.
Market Access
Market access considerations are integrated into development planning to support long-term value realization. G-Plume’s approach aligns clinical evidence generation with payer, policy, and access requirements in global markets.
